Literature DB >> 25292037

Mechanism of fatty acid synthase in drug tolerance related to epithelial-mesenchymal transition of breast cancer.

Jun-Qin Li1, Hui Xue, Lan Zhou, Li-Hua Dong, Da-Peng Wei, Hua Li.   

Abstract

OBJECTIVE: The mechanism of action of fatty acid synthase (FASN) in drug tolerance of breast cancer cells with epithelial-mesenchymal transition (EMT) features was investigated.
METHODS: The breast cancer cell line MCF-7-MEK5 with stably occurring EMT and tumour necrosis factor-α (TNF-α) tolerance was used as the experimental model, whereas MCF-7 acted as the control. Tumour cells were implanted into nude mice for in vivo analysis, and cerulenin was used as a FASN inhibitor. RT-PCR, real-time quantitative PCR and Western blot were employed to detect the expression of FASN, TNFR-1, TNFR-2, Wnt-1, β-catenin and cytC at the RNA and protein levels.
RESULTS: Compared with MCF-7, TNFR-1 expression in MCF-7-MEK5 was slightly changed, TNFR-2 was decreased, and FASN, Wnt-1, β-catenin and cytC were increased. The expression of Wnt-1 and β-catenin in MCF-7-MEK5 decreased after cerulenin treatment, whereas cytC expression increased.
CONCLUSIONS: The important function of FASN in the drug tolerance of breast cancer may be due to the following mechanisms: FASN downregulated TNFR-2 expression through lipid rafts to make the cells less sensitive to TNF-α, and simultaneously activated the Wnt-1/β-catenin signalling pathway. Thus, cytC expression increased, which provided cells with anti-apoptotic capacity and induced drug tolerance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25292037     DOI: 10.7314/apjcp.2014.15.18.7617

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  2 in total

1.  Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.

Authors:  Sudeshna Goswami; Neelam Sharma-Walia
Journal:  Oncotarget       Date:  2016-09-13

Review 2.  Tumor Necrosis Factor Receptors: Pleiotropic Signaling Complexes and Their Differential Effects.

Authors:  Portia Gough; Ian A Myles
Journal:  Front Immunol       Date:  2020-11-25       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.